ExecutiveOrdersEO
EO 14187Executive OrderTrump 47 · R

Executive Order 14187

Protecting Children From Chemical and Surgical Mutilation

This executive order prohibits federal funding, sponsorship, or support for pediatric gender-affirming medical care, defining such treatments as "chemical and surgical mutilation" for individuals under 19. It directs multiple agencies to rescind supportive policies, exclude coverage from federal health programs (Medicaid, Medicare, TRICARE, FEHB/PSHB), prioritize enforcement of existing laws, and promote new legislation creating private rights of action for affected children and parents.

Federal Register Open PDF 90 FR 8771

Impact dates

  1. FEHB/PSHB 2026 Plan Year call letter exclusions take effect (plan year beginning)

  2. HHS literature review on best practices for minors with gender dysphoria

  3. Agency heads submit combined implementation report to Assistant to President for Domestic Policy

Key directives

  • Agencies shall rescind or amend all policies relying on WPATH guidance
  • HHS Secretary shall publish literature review within 90 days
  • Agency heads shall ensure federal grant recipients end pediatric gender-affirming care
  • HHS Secretary shall withdraw March 2, 2022 guidance and issue whistleblower protections
  • HHS shall take regulatory/sub-regulatory actions under Medicare, Medicaid, ACA Section 1557, EHB requirements, ICD-11, DSM-5
  • Secretary of Defense shall commence rulemaking to exclude care from TRICARE and amend provider handbook
  • OPM Director shall exclude pediatric transgender surgeries and hormone treatments from FEHB/PSHB 2026 Plan Year and negotiate premium reductions
  • Attorney General shall prioritize enforcement of 18 U.S.C. § 116 (female genital mutilation), convene state AGs, investigate fraud and FDCA violations, draft legislation for private right of action, and investigate 'sanctuary States' for parental custody practices
  • Agency heads shall submit combined progress report within 60 days

Who is ordered

Timeline

Immediate

  • Federal agencies must rescind/amend policies relying on WPATH guidance
  • Agency heads must take steps to end federal grant funding for institutions providing pediatric gender-affirming care
  • HHS must withdraw March 2, 2022 gender-affirming care guidance
  • Secretary of Defense must commence rulemaking to exclude coverage from TRICARE

Near term (90d)

  • HHS Secretary must publish literature review on best practices for minors with gender dysphoria (within 90 days)
  • Agency heads must submit combined implementation report to Assistant to President for Domestic Policy (within 60 days)
  • OPM must include FEHB/PSHB exclusion provisions in 2026 Plan Year call letter

Long term

  • FEHB/PSHB coverage exclusions take effect for 2026 Plan Year
  • Potential TRICARE rulemaking completion
  • DOJ to draft/promote legislation for private right of action
  • Ongoing enforcement actions against states and providers

Risks & tensions

  • Legal challenges likely on Equal Protection and ACA grounds; Section 1557 and EHB modifications may conflict with existing regulations
  • Definition of 'child' as under 19 exceeds typical medical adulthood thresholds, expanding scope beyond standard pediatric definitions
  • Conflation of gender-affirming care with female genital mutilation (18 U.S.C. § 116) creates interpretive tension; statute does not clearly cover these procedures
  • State 'sanctuary' policies and parental custody provisions may trigger federalism conflicts; Parental Kidnaping Prevention Act application uncertain
  • Whistleblower protections and DOJ fraud investigations could chill provider participation even where care remains legal
  • Immediate grant funding threats to medical institutions may disrupt research and education programs beyond targeted care
  • TRICARE rulemaking timeline unspecified; 'commence' language allows extended delay
Executive Order 14187: Protecting Children From Chemical and Surgical Mutilation · Executive Orders